Seven Bridges Advisors LLC boosted its stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 33.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 22,503 shares of the company’s stock after buying an additional 5,681 shares during the period. Seven Bridges Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $1,130,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Flow Traders U.S. LLC purchased a new stake in Teva Pharmaceutical Industries during the first quarter valued at $105,000. Kistler Tiffany Companies LLC boosted its stake in Teva Pharmaceutical Industries by 3.1% in the second quarter. Kistler Tiffany Companies LLC now owns 2,135 shares of the company’s stock valued at $107,000 after buying an additional 64 shares in the last quarter. Massmutual Trust Co. FSB ADV boosted its stake in Teva Pharmaceutical Industries by 1,127.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,210 shares of the company’s stock valued at $118,000 after buying an additional 2,030 shares in the last quarter. Cribstone Capital Management LLC purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at $161,000. Finally, Carroll Financial Associates Inc. boosted its stake in Teva Pharmaceutical Industries by 3.2% in the second quarter. Carroll Financial Associates Inc. now owns 3,249 shares of the company’s stock valued at $163,000 after buying an additional 100 shares in the last quarter.

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) traded down 0.67% during trading on Tuesday, hitting $50.36. The company had a trading volume of 3,440,644 shares. The company’s 50 day moving average is $52.25 and its 200 day moving average is $53.29. Teva Pharmaceutical Industries Ltd has a 1-year low of $48.01 and a 1-year high of $66.55. The firm has a market capitalization of $46.03 billion, a P/E ratio of 33.64 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.20 by $0.05. The firm earned $5 billion during the quarter, compared to the consensus estimate of $4.86 billion. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.43 EPS. Analysts anticipate that Teva Pharmaceutical Industries Ltd will post $5.26 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Monday, August 22nd were given a $0.34 dividend. The ex-dividend date was Thursday, August 18th. This represents a $1.36 dividend on an annualized basis and a yield of 2.70%.

Several equities research analysts recently weighed in on TEVA shares. Goldman Sachs Group Inc. cut their price objective on shares of Teva Pharmaceutical Industries from $70.00 to $60.00 in a research report on Sunday, July 17th. Mizuho reaffirmed a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Tuesday, May 31st. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Tuesday, May 31st. Citigroup Inc. reaffirmed a “buy” rating and set a $75.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Monday, June 13th. Finally, Oppenheimer Holdings Inc. reaffirmed a “buy” rating and set a $77.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Wednesday, June 8th. Seven research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $67.54.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.